Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Decrease in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a large decrease in short interest in August. As of August 14th, there was short interest totaling 42,034 shares, a decrease of 35.9% from the July 30th total of 65,538 shares. Based on an average daily trading volume, of 28,832 shares, the short-interest ratio is presently 1.5 days. Currently, 0.8% of the company’s stock are sold short.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright lowered Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Finally, Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Neuphoria Therapeutics currently has an average rating of “Hold” and an average target price of $21.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Merck & Co. Inc. acquired a new position in shares of Neuphoria Therapeutics during the 2nd quarter worth about $43,818. Commonwealth Equity Services LLC acquired a new stake in Neuphoria Therapeutics in the 4th quarter worth about $43,000. XTX Topco Ltd acquired a new stake in Neuphoria Therapeutics in the 4th quarter worth about $47,000. Persistent Asset Partners Ltd increased its stake in Neuphoria Therapeutics by 173.1% during the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after buying an additional 8,495 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Neuphoria Therapeutics during the 4th quarter worth approximately $54,000. 15.90% of the stock is owned by institutional investors and hedge funds.

Neuphoria Therapeutics Stock Up 0.3%

Shares of NEUP stock traded up $0.01 on Wednesday, hitting $3.80. The company had a trading volume of 4,809 shares, compared to its average volume of 103,438. The firm has a market cap of $20.52 million, a P/E ratio of -0.34 and a beta of 0.75. The company has a 50-day moving average price of $3.79 and a 200-day moving average price of $4.36. Neuphoria Therapeutics has a twelve month low of $3.19 and a twelve month high of $21.40.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.